Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Syrentis Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,037,004

124 payments

Through program year 2024, Syrentis Clinical Research is reported as receiving $3,037,004 in research payments, across 124 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $177,428 15
2023 Research $561,340 21
2022 Research $318,329 18
2021 Research $306,337 21
2020 Research $370,817 29
2019 Research $1,302,753 20

Breakdown

Who paid Research payments · program years 2019–2024
  1. Eisai Inc. $1,100,275 58 payments
  2. Biogen, Inc. $976,736 5 payments
  3. Novartis Pharmaceuticals Corporation $446,863 9 payments
  4. Genentech, Inc. $289,477 20 payments
  5. Perrigo Company plc $80,100 4 payments
  6. Avanir Pharmaceuticals, Inc. $62,825 11 payments
  7. ACADIA Pharmaceuticals Inc $49,911 10 payments
  8. Chiesi USA, Inc. $18,928 4 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $11,100 2 payments
  10. AbbVie, Inc. $789 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,100,275 58 payments
  2. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $426,214 1 payment
  3. Gantenerumab in Early Ad $289,477 20 payments
  4. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $285,539 2 payments
  5. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $278,636 1 payment
  6. Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 $145,616 2 payments
  7. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $126,270 1 payment
  8. Bioequivalence study between Perrigo's product and Epiduo Forte Gel $80,100 4 payments
  9. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $66,630 1 payment
  10. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $64,316 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record